{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T18:32:45Z","timestamp":1790188365767,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103016"],"award-info":[{"award-number":["82103016"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972258"],"award-info":[{"award-number":["81972258"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82102958"],"award-info":[{"award-number":["82102958"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003345","name":"Chinese Academy of Meteorological Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003345","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2018YFE0118600"],"award-info":[{"award-number":["2018YFE0118600"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332022115"],"award-info":[{"award-number":["3332022115"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"CAMS Innovation Fund for Medical Sciences","doi-asserted-by":"publisher","award":["2021-1-I2M \u2212 002"],"award-info":[{"award-number":["2021-1-I2M \u2212 002"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Letters"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.canlet.2022.216020","type":"journal-article","created":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T15:27:53Z","timestamp":1669390073000},"page":"216020","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":28,"special_numbering":"C","title":["mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox\/+LSL-KrasG12D\/+Pdx-1-Cre murine models"],"prefix":"10.1016","volume":"554","author":[{"given":"Jiangdong","family":"Qiu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyu","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueze","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.canlet.2022.216020_bib1","doi-asserted-by":"crossref","first-page":"2913","DOI":"10.1158\/0008-5472.CAN-14-0155","article-title":"Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States","volume":"74","author":"Rahib","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.canlet.2022.216020_bib2","first-page":"7","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA A Cancer J. Clin."},{"key":"10.1016\/j.canlet.2022.216020_bib3","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/JP9.0000000000000012","article-title":"The current surgical treatment of pancreatic cancer in China: a national wide cross-sectional study","volume":"2","author":"Wu","year":"2019","journal-title":"J. Pancreatol."},{"key":"10.1016\/j.canlet.2022.216020_bib4","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1634\/theoncologist.2019-IO-S1-s05","article-title":"PD-1\/PD-L1 blockade therapy in advanced non-small-cell lung cancer: current status and future directions","volume":"24","author":"Xia","year":"2019","journal-title":"Oncol."},{"key":"10.1016\/j.canlet.2022.216020_bib5","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1016\/j.clinthera.2015.02.018","article-title":"The next immune-checkpoint inhibitors: PD-1\/PD-L1 blockade in melanoma","volume":"37","author":"Mahoney","year":"2015","journal-title":"Clin. Therapeut."},{"key":"10.1016\/j.canlet.2022.216020_bib6","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gutjnl-2016-311585","article-title":"IL-6 and PD-L1 antibody blockade combination therapy reduces tumour progression in murine models of pancreatic cancer","volume":"67","author":"Mace","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.canlet.2022.216020_bib7","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.canlet.2017.08.006","article-title":"PD-1\/PD-L1 and immunotherapy for pancreatic cancer","volume":"407","author":"Feng","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.canlet.2022.216020_bib8","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/s41590-020-0761-y","article-title":"Regulation and modulation of antitumor immunity in pancreatic cancer","volume":"21","author":"Leinwand","year":"2020","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.canlet.2022.216020_bib9","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1007\/s10620-020-06183-9","article-title":"Dilemma and challenge of immunotherapy for pancreatic cancer","volume":"66","author":"Wu","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.canlet.2022.216020_bib10","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21197307","article-title":"The immune microenvironment in pancreatic cancer","volume":"21","author":"Huber","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.canlet.2022.216020_bib11","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1038\/s41568-018-0074-8","article-title":"mTOR signalling and cellular metabolism are mutual determinants in cancer","volume":"18","author":"Mossmann","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.canlet.2022.216020_bib12","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.semcancer.2019.07.003","article-title":"mTOR: role in cancer, metastasis and drug resistance","volume":"59","author":"Murugan","year":"2019","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2022.216020_bib13","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/s13046-018-0947-4","article-title":"LAT2 regulates glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer","volume":"37","author":"Feng","year":"2018","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.216020_bib14","first-page":"1766","article-title":"PTEN\/PI3K\/mTOR\/B7-H1 signaling pathway regulates cell progression and immuno-resistance in pancreatic cancer","volume":"60","author":"Zhang","year":"2013","journal-title":"Hepato-Gastroenterology"},{"key":"10.1016\/j.canlet.2022.216020_bib15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.semcancer.2017.04.015","article-title":"PI3K-AKT-mTOR inhibition in cancer immunotherapy, redux","volume":"48","author":"O'Donnell","year":"2018","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.canlet.2022.216020_bib16","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1158\/2159-8290.CD-15-0283","article-title":"Loss of PTEN promotes resistance to T cell-mediated immunotherapy","volume":"6","author":"Peng","year":"2016","journal-title":"Cancer Discov."},{"key":"10.1016\/j.canlet.2022.216020_bib17","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.2217\/imt.14.84","article-title":"mTOR signaling, Tregs and immune modulation","volume":"6","author":"Chapman","year":"2014","journal-title":"Immunotherapy"},{"key":"10.1016\/j.canlet.2022.216020_bib18","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ccell.2017.01.004","article-title":"Inactivation of interferon receptor promotes the establishment of immune privileged tumor microenvironment","volume":"31","author":"Katlinski","year":"2017","journal-title":"Cancer Cell"},{"key":"10.1016\/j.canlet.2022.216020_bib19","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1053\/j.gastro.2020.03.018","article-title":"Combination of PD-1 inhibitor and OX40 agonist induces tumor rejection and immune memory in mouse models of pancreatic cancer","volume":"159","author":"Ma","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.canlet.2022.216020_bib20","article-title":"Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-PD-1","volume":"8","author":"Liu","year":"2021","journal-title":"Adv. Sci."},{"key":"10.1016\/j.canlet.2022.216020_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/CJI.0000000000000062","article-title":"PD-1\/PD-L1 blockade together with vaccine therapy facilitates effector T-cell infiltration into pancreatic tumors","volume":"38","author":"Soares","year":"2015","journal-title":"J. Immunother."},{"key":"10.1016\/j.canlet.2022.216020_bib22","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/s41577-021-00541-y","article-title":"Metabolic barriers to cancer immunotherapy","volume":"21","author":"DePeaux","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2022.216020_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/s12943-020-01169-7","article-title":"Metabolism of pancreatic cancer: paving the way to better anticancer strategies","volume":"19","author":"Qin","year":"2020","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.canlet.2022.216020_bib24","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.cell.2015.08.012","article-title":"Phosphoenolpyruvate is a metabolic checkpoint of anti-tumor T cell responses","volume":"162","author":"Ho","year":"2015","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.216020_bib25","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1016\/j.cell.2013.05.016","article-title":"Posttranscriptional control of T cell effector function by aerobic glycolysis","volume":"153","author":"Chang","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.canlet.2022.216020_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1218297","article-title":"Unravelling the interplay between extracellular acidosis and immune cells","volume":"2018","author":"Erra D\u00edaz","year":"2018","journal-title":"Mediat. Inflamm."},{"key":"10.1016\/j.canlet.2022.216020_bib27","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001367","article-title":"Combination of gemcitabine and anti-PD-1 antibody enhances the anticancer effect of M1 macrophages and the Th1 response in a murine model of pancreatic cancer liver metastasis","volume":"8","author":"Ho","year":"2020","journal-title":"J. Immunother. Cancer."},{"key":"10.1016\/j.canlet.2022.216020_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.celrep.2019.08.068","article-title":"Restricting glycolysis preserves T cell effector functions and augments checkpoint therapy","volume":"29","author":"Renner","year":"2019","journal-title":"Cell Rep."},{"key":"10.1016\/j.canlet.2022.216020_bib29","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.cytogfr.2017.04.003","article-title":"Dysfunctional T cell metabolism in the tumor microenvironment","volume":"35","author":"Beckermann","year":"2017","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.canlet.2022.216020_bib30","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1016\/j.etap.2012.06.011","article-title":"In vitro and in vivo studies of the toxic effects of perfluorononanoic acid on rat hepatocytes and Kupffer cells","volume":"34","author":"Fang","year":"2012","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"10.1016\/j.canlet.2022.216020_bib31","doi-asserted-by":"crossref","first-page":"L678","DOI":"10.1152\/ajplung.00518.2016","article-title":"Nonantibiotic macrolides restore airway macrophage phagocytic function with potential anti-inflammatory effects in chronic lung diseases","volume":"312","author":"Hodge","year":"2017","journal-title":"Am. J. Physiol. Lung Cell Mol. Physiol."},{"key":"10.1016\/j.canlet.2022.216020_bib32","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/odi.12908","article-title":"Alteration of macrophage viability, differentiation, and function by bisphosphonates","volume":"24","author":"Patntirapong","year":"2018","journal-title":"Oral Dis."},{"key":"10.1016\/j.canlet.2022.216020_bib33","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1248\/bpb.22.647","article-title":"Inhibitory effects of hydrolyzable tannins from Melastoma dodecandrum Lour. on nitric oxide production by a murine macrophage-like cell line, RAW264.7, activated with lipopolysaccharide and interferon-gamma","volume":"22","author":"Ishii","year":"1999","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.canlet.2022.216020_bib34","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1161\/HYPERTENSIONAHA.117.09815","article-title":"Inhibition of aneurysm progression by direct renin inhibition in a rabbit model","volume":"70","author":"Miyake","year":"2017","journal-title":"Hypertension"},{"key":"10.1016\/j.canlet.2022.216020_bib35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0070002","article-title":"Oxidized phospholipids induce ceramide accumulation in RAW 264.7 macrophages: role of ceramide synthases","volume":"8","author":"Halasiddappa","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.canlet.2022.216020_bib36","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/gt.2010.104","article-title":"The combination of immunosuppression and carrier cells significantly enhances the efficacy of oncolytic poxvirus in the pre-immunized host","volume":"17","author":"Guo","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.canlet.2022.216020_bib37","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1093\/carcin\/bgs319","article-title":"The combination of the histone deacetylase inhibitor vorinostat and synthetic triterpenoids reduces tumorigenesis in mouse models of cancer","volume":"34","author":"Tran","year":"2013","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.canlet.2022.216020_bib38","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.cmet.2019.06.001","article-title":"Macrophages and metabolism in the tumor microenvironment","volume":"30","author":"Vitale","year":"2019","journal-title":"Cell Metabol."},{"key":"10.1016\/j.canlet.2022.216020_bib39","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nri3901","article-title":"Regulation of innate immune cell function by mTOR","volume":"15","author":"Weichhart","year":"2015","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.canlet.2022.216020_bib40","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00018-019-03278-z","article-title":"The enhancement of glycolysis regulates pancreatic cancer metastasis","volume":"77","author":"Yang","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.canlet.2022.216020_bib41","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1186\/s13046-020-01765-x","article-title":"Glycometabolic rearrangements--aerobic glycolysis in pancreatic cancer: causes, characteristics and clinical applications","volume":"39","author":"Cao","year":"2020","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.canlet.2022.216020_bib42","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.trecan.2019.10.007","article-title":"Metabolic regulation of macrophage polarization in cancer","volume":"5","author":"Mehla","year":"2019","journal-title":"Trends Cancer."}],"container-title":["Cancer Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522005079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0304383522005079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T16:06:42Z","timestamp":1759594002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0304383522005079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":42,"alternative-id":["S0304383522005079"],"URL":"https:\/\/doi.org\/10.1016\/j.canlet.2022.216020","relation":{},"ISSN":["0304-3835"],"issn-type":[{"value":"0304-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53flox\/+LSL-KrasG12D\/+Pdx-1-Cre murine models","name":"articletitle","label":"Article Title"},{"value":"Cancer Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.canlet.2022.216020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"216020"}}